Mameghan H, Fisher R, Mameghan J, Brook S
Department of Radiation Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Aust N Z J Surg. 1994 Jun;64(6):389-94. doi: 10.1111/j.1445-2197.1994.tb02236.x.
The results of external beam radiotherapy for clinically localized adenocarcinoma of the prostate in 448 patients treated in the period 1980-90 were reviewed. The average follow up was 4.9 years. The patients were aged 44-87 years (median 69 years) and all had histopathological evidence of adenocarcinoma by needle biopsy or transurethral resection of prostate. The histopathological grading was: 127 G1; 154 G2; 127 G4; 28 Gx. Clinical staging according to TNM (American Urological Association) was: 29 T0 (A2); 4 T1 (B1); 173 T2 (B2); 176 T3 (C1); 63 T4 (C2); 3 Tx. Routine surgical pelvic lymph node staging was not performed but patients had radiological (computerized tomography scan or lymphogram) nodal staging: 350 N0; 22 N1; 12 N2; 64 Nx. High energy linear accelerator external beam radiotherapy was given by multiple fields to total doses of 50-70 Gy (median 60 Gy). The majority of patients (307, 69%) was treated by a uniform policy under the care of one radiation oncologist (HM). The rates of local and distant failure at 5 years were 10% (s.e. = 2%) and 42% (s.e. = 3%), respectively. The late complication rate at 5 years was 25% (s.e. = 2%), comprising mild 16%, moderate 7% and severe 1.3%. The 5 year overall survival rate was 64% (s.e. = 2%) and the cancer-specific survival rate was 74% (s.e. = 3%). Both histological grade and clinical stage were strongly predictive of overall survival and distant failure. Only histological grade was predictive of local failure.(ABSTRACT TRUNCATED AT 250 WORDS)
回顾了1980年至1990年期间接受治疗的448例临床局限性前列腺腺癌患者的外照射放疗结果。平均随访时间为4.9年。患者年龄在44至87岁之间(中位年龄69岁),所有患者均通过针吸活检或经尿道前列腺切除术获得腺癌的组织病理学证据。组织病理学分级为:127例G1;154例G2;127例G4;28例Gx。根据TNM(美国泌尿外科学会)进行的临床分期为:29例T0(A2);4例T1(B1);173例T2(B2);176例T3(C1);63例T4(C2);3例Tx。未进行常规手术盆腔淋巴结分期,但患者进行了放射学(计算机断层扫描或淋巴管造影)淋巴结分期:350例N0;22例N1;12例N2;64例Nx。采用多野给予高能直线加速器外照射放疗,总剂量为50 - 70 Gy(中位剂量60 Gy)。大多数患者(307例,69%)在一位放射肿瘤学家(HM)的照料下采用统一方案进行治疗。5年时局部和远处失败率分别为10%(标准误 = 2%)和42%(标准误 = 3%)。5年时晚期并发症发生率为25%(标准误 = 2%),其中轻度占16%,中度占7%,重度占1.3%。5年总生存率为64%(标准误 = 2%),癌症特异性生存率为74%(标准误 = 3%)。组织学分级和临床分期均强烈预测总生存率和远处失败。只有组织学分级可预测局部失败。(摘要截取自250字)